Tofacitinib Improves Composite Endpoint Measures of Disease in Patients with Psoriatic Arthritis

被引：0
|
作者：
Helliwell, Philip S. [1 ]
Coates, Laura C. [1 ]
FitzGerald, Oliver [2 ]
Nash, Peter [3 ]
Soriano, Enrique R. [4 ]
Husni, M. Elaine [5 ]
Hsu, Ming-Ann [6 ]
Kanik, Keith S. [6 ]
Hendrikx, Thijs [7 ]
Wu, Joseph [6 ]
Kudlacz, Elizabeth [6 ]
机构：
[1] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England
[2] ASRI, Dublin, Ireland
[3] Univ Queensland, Dept Med, Brisbane, Qld, Australia
[4] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina
[5] Cleveland Clin, Lerner Res Inst, Cleveland, OH 44106 USA
[6] Pfizer Inc, Groton, CT 06340 USA
[7] Pfizer Inc, Collegeville, PA USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
623
引用
收藏
页数：2
相关论文
共 50 条
  • [1] TOFACITINIB IMPROVES COMPOSITE ENDPOINT MEASURES OF DISEASE IN PATIENTS WITH PSORIATIC ARTHRITIS
    Helliwell, P.
    Coates, L. C.
    FitzGerald, O.
    Nash, P.
    Soriano, E. R.
    Husni, M. E.
    Hsu, M. -A.
    Kanik, K. S.
    Hendrikx, T.
    Wu, J.
    Kudlacz, E.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 379 - 380
  • [2] TOFACITINIB IMPROVES COMPOSITE ENDPOINT MEASURES OF DISEASE IN PATIENTS WITH PSORIATIC ARTHRITIS
    Helliwell, P.
    Coates, L. C.
    FitzGerald, O.
    Nash, P.
    Soriano, E. R.
    Husni, E.
    Hsu, M-A
    Kanik, K. S.
    Hendrikx, T.
    Wu, J.
    Kudlacz, E.
    [J]. INTERNAL MEDICINE JOURNAL, 2018, 48 : 14 - 15
  • [3] TOFACITINIB IMPROVES COMPOSITE ENDPOINT MEASURES OF DISEASE IN PATIENTS WITH PSORIATIC ARTHRITIS
    Helliwell, P.
    Coates, L. C.
    FitzGerald, O.
    Nash, P.
    Soriano, E. R.
    Husni, M. E.
    Hsu, M. A.
    Kanik, K. S.
    Hendrikx, T.
    Wu, J.
    Kudlacz, E.
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S110 - S110
  • [4] Tofacitinib in psoriatic arthritis
    Wang, Ting-Shun
    Tsai, Tsen-Fang
    [J]. IMMUNOTHERAPY, 2017, 9 (14) : 1153 - 1163
  • [5] Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis
    Xie, Rujia
    Deng, Chenhui
    Wang, Qiang
    Kanik, Keith S.
    Nicholas, Timothy
    Menon, Sujatha
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2019, 57 (09) : 464 - 473
  • [6] Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
    Laura C. Coates
    Andrew G. Bushmakin
    Oliver FitzGerald
    Dafna D. Gladman
    Lara Fallon
    Joseph C. Cappelleri
    Ming-Ann Hsu
    Philip S. Helliwell
    [J]. Arthritis Research & Therapy, 23
  • [7] Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
    Coates, Laura C.
    Bushmakin, Andrew G.
    FitzGerald, Oliver
    Gladman, Dafna D.
    Fallon, Lara
    Cappelleri, Joseph C.
    Hsu, Ming-Ann
    Helliwell, Philip S.
    [J]. ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
  • [8] Optimal composite measures for psoriatic arthritis
    Huang, Jin-Xian
    Lee, Yung-Heng
    Wei, James Cheng-Chung
    [J]. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2023, 26 (10) : 1897 - 1898
  • [9] Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis
    Nell-Duxneuner, Valerie P.
    Stamm, Tanja A.
    Machold, Klaus P.
    Pflugbeil, Stephan
    Aletaha, Daniel
    Smolen, Josef S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (03) : 546 - 549
  • [10] Efficacy of Tofacitinib on Enthesitis in Patients with Active Psoriatic Arthritis
    Mease, Philip
    Orbai, Ana-Maria
    FitzGerald, Oliver
    Bedaiwi, Mohamed
    Fleishaker, Dona L.
    Mundayat, Rajiv
    Young, Pamela
    Helliwell, Philip S.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3774 - 3776
12345